Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate patient perceptions of olopatadine 0.2% dosed once daily in patients previously treated with twice-daily, topical, ocular, anti-allergy medications.

Conditions
-----------------
Allergic Conjunctivitis

Intervention / Treatment
-----------------
* Drug: Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 12 years of age or older. History (within the past 24 months) of allergic conjunctivitis. Active signs and symptoms of ocular allergies. Ocular health within normal limits, as determined by the investigator or subinvestigator. Willing to avoid contact lens wear each study visit immediately prior to study medication instillation and for 10 minutes after instillation of study drug. Other protocol-defined inclusion criteria may apply. Exclusion Criteria: Contraindications or hypersensitivity to study medication or its components. One sighted eye or not correctable to 0.6 logMAR or better in both eyes at the screening visit. Known history of recurrent corneal erosion syndrome. Ocular trauma or surgical intervention within 6 months prior to Visit 1. Participation in any other investigational study within 30 days before Visit 1. Pregnant or nursing. Other protocol-defined exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Olopatadine 0.2%<br>1 drop self-administered in each eye once daily in the morning for 7 days | Drug: Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)<br>* Commercially marketed ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis<br>* Other names: Pataday®;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall Patient Satisfaction | Overall satisfaction was assessed by the patient on a questionnaire. The patient was instructed to select a single response to the statement, Overall, how satisfied are you with your current eye allergy medication? A 5-point scale was used: very satisfied, satisfied, undecided, dissatisfied, very dissatisfied. Results are reported as the percentage of patients who responded, very satisfied or satisfied. | Day 0 | 
| Overall Patient Satisfaction | Overall satisfaction was assessed by the patient on a questionnaire. The patient was instructed to select a single response to the statement, Overall, how satisfied were you with olopatadine 0.2%? A 5-point scale was used: very satisfied, satisfied, undecided, dissatisfied, very dissatisfied. Results are reported as the percentage of patients who responded, very satisfied or satisfied. | Day 7 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Allergic conjunctivitis